Regado Biosciences declared the Journal of Thrombosis and Haemostasis, the authorised book of the International Society on Thrombosis and Haemostasis, has publicised the Phase 1c clinical results of the Company’s REG1 anticoagulation system. REG1 is a two-component grouping comprised of an aptamer-based anticoagulant, RB006, and its matching antidote, RB007, which binds to and neutralizes RB006.